TY - JOUR
T1 - Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas
T2 - A RANO review
AU - Nayak, Lakshmi
AU - Bettegowda, Chetan
AU - Scherer, Florian
AU - Galldiks, Norbert
AU - Ahluwalia, Manmeet
AU - Baraniskin, Alexander
AU - von Baumgarten, Louisa
AU - Bromberg, Jacoline E.C.
AU - Ferreri, Andrés J.M.
AU - Grommes, Christian
AU - Hoang-Xuan, Khê
AU - Kühn, Julia
AU - Rubenstein, James L.
AU - Rudà, Roberta
AU - Weller, Michael
AU - Chang, Susan M.
AU - van den Bent, Martin J.
AU - Wen, Patrick Y.
AU - Soffietti, Riccardo
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact jou
PY - 2024/6/1
Y1 - 2024/6/1
N2 - BACKGROUND: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors. METHODS: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and cerebrospinal fluid (CSF)-liquid biopsy in CNS lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL). RESULTS: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, and steroid responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments, and prediction of outcome. CONCLUSIONS: Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.
AB - BACKGROUND: The utility of liquid biopsies is well documented in several extracranial and intracranial (brain/leptomeningeal metastases, gliomas) tumors. METHODS: The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and cerebrospinal fluid (CSF)-liquid biopsy in CNS lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL). RESULTS: Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, and steroid responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments, and prediction of outcome. CONCLUSIONS: Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85195228411&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noae032
DO - 10.1093/neuonc/noae032
M3 - Review article
C2 - 38598668
AN - SCOPUS:85195228411
SN - 1522-8517
VL - 26
SP - 993
EP - 1011
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 6
ER -
